This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Eugenia Buil, MD; Cristina Manso, MD; Francesc Vidal, PhD; Joaquim Peraire, MD; Cristobal Richart, PhD
Tarragona, Spain

Arch Intern Med. 1997;157(12):1391-1392.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We read with interest the recent article in the ARCHIVES by Graham et al¹ regarding the effect of isoniazid chemoprophylaxis on patients infected with human immunodeficiency virus (HIV). Their results showed a significant decrease in the incidence of mycobacterial disease in patients who were treated with isoniazid at various dosages during a 12-month period. However, it is not clear what happened when the secondary prophylaxis was stopped. In this regard, some reports² have recommended lifelong isoniazid chemoprophylaxis, whereas others³ argue against it. We present a case that illustrates that a 12-month regimen may not be enough for all patients.

Human immunodeficiency virus type 1 (HIV-1) infection, acquired by heterosexual transmission, was diagnosed in a 32-year-old woman in 1986. Since then, her blood lymphocyte CD4 cell count had been above 0.70x10⁹/L. The patient's condition was categorized as long-term and nonprogressive; therefore, she had never received antiretroviral . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?